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Background
Hypertrophic Cardiomyopathy (HCM) is an autosomal dominant disorder due to mutations in sacromeric genes 
with variable penetrance. Hypertrophic Obstructive Cardiomyopathy (HOCM) is a major complication of Hypertrophic 
Cardiomyopathy. Unexplained hypertrophy in the Left Ventricle (LV) or Intraventricular Septum (IVS) had been the 
diagnostic criterion for HCM which is more often confirmed by the echocardiography [1]. The frequency of HCM 
in general population is 1:500 and about 60-70% genetic predisposition is known [2]. It has been observed that 
mutations in the Cardiac myosin binding protein C (MYBPC3) gene causes late onset of disease with mild symptoms 
while mutations in the Beta Myosin Heavy chain (MYH7) gene leads to early onset with severe symptoms. Apart 
from Epigenetic and Environmental factors, modifier genes further complicate the situation leading to altered clinical 
outcome even among the same family members having identical mutation [3].
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Aims
Present study was designed to evaluate genotype–phenotype 
correlation in the Index patient and family members harboring a rare 
mutation in MYH7 (C  T at codon 923) gene and suffering from 
Hypertrophic Obstructive Cardiomyopathy (HOCM).
Materials and Methods
Total 8 individuals of a family of an index patient were included 
in this study in which father and youngest son diagnosed with 
hypertrophic Obstructive cardiomyopathy. All family members were 
screened with ECG, Echocardiography and clinical evaluation was 
done by the cardiologists as per the WHO criteria for diagnosis of 
HCM (1996) [4]. 5mL of intravenous blood was collected along with 
other physiological and physical parameters and DNA was extracted 
from blood by Phenol-chloroform method [5]. Suitable primers [6] 
were used to amplify exon 23 of MYH7 gene, and the PCR product 
(390bp) was sequenced in an automated sequencer ABI 3700 by 
Sanger’s method (Figure 1A). The study was ethically approved by 
institutional committee and informed written consent was taken from 
all participants.
Screening for other known mutations associated with HCM like 
E101K in Cardiac muscle Actin (ACTC) gene [7] and P77L in Cardiac 
Troponin T (TNNT2) gene [8] were done by RFLP method using 
enzymes Ava I and Sm1I respectively. 5bp deletion polymorphism 
in intron 3 of TNNT2 gene was also analyzed by RFLP method using 
Ear I enzyme and genotyped in 8% Polyacrylamide gel (Figure 1B). 
287bp Deletion polymorphism of Angiotensin Converting Enzyme 
(ACE) gene in the intron16 [9] and 25bp Deletion Polymorphism in 
Cardiac Myosin Binding Protein C (MYBPC3) gene in the intron 32 
[10] were analyzed directly by genotyping the PCR product on 2%
(Figure 1C) and 3% Agarose gel respectively. To validate MYH7 (CT
at codon 923) mutation, 20 HCM families including 21 affected and 46
unaffected family members were screened for exon 23 of MYH7 gene
by Sanger sequencing. All sequences were deposited in NCBI data base
[GenBank accession nos. JX504729 - JX504803].
Results and Discussions
The rod region of alpha helical segment connecting myosin head to 
thick filament results in possible dysfunction in contraction indicating 
a functional role for variants in MYH7 gene [11]. The rare MYH7 
mutation reported in the index family was not found in other 20 HCM 
families in our study.
The symptoms of HOCM (Hypertrophic obstructive 
cardiomyopathy) such as dyspnea and angina were observed in the 
patient at the age of 14 during sports activity performance. Preliminary 
ECG examination indicated signs of ischemic heart disease which was 
confirmed as HOCM by the echocardiographic examination. 
Screening of all family members established presence of HOCM 
in father, who had very mild symptoms from the past 3yrs but avoided 
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Figure 1: (A) Sequence region of exon 23 of MYH7 showing heterozygous 
mutation CT at codon 923. (B) PAGE showing homozygous wild (II) with 
band size 108bp and 84bp, heterozygous (ID) with band size 108bp, 102bp 
and 84bp and homozygous mutant 108bp and 102bp. (C) ACE genotyping in 
2% Agarose Gel with homozygous wild (II) with band size 490bp, Heterozygous 
(ID) with band size 490bp and 190bp and homozygous mutant 190bp. (I: 
Insertion; D: Deletion: L: DNA Ladder).
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medical checkup. Figure 2 shows the dominant pattern of inheritance 
of the MYH7 (CT at codon 923) mutation. The index patient and one 
of his elder brothers (20 years) inherited the same mutation from their 
father. The father’s sisters, mother and his eldest brother was devoid 
of this mutation. This rare variant had been reported previously in 
an Indian HCM family and also in European cohort of 1000 genome 
project (www.ensemble.org). 
The inference from the clinical parameters is depicted in table 
1 in consonance with the genotypes. Abnormal ECG and 2D 
echocardiography revealed hypertrophied LV in index patient and 
his father only. The Blood Pressure and BMI of the index patient and 
the father were normal which excludes them from other hypertension 
which can also lead to hypertrophied LV. It was pertinent to note that 
the father had late onset of the disease (48yrs) while the youngest son 
(index patient) had early onset of the disease at the age of 14 years and 
the elder son (20 yrs) was asymptomatic though all three were having 
the rare MYH7 mutation. 
The Cardiac Troponin T (TNNT2) protein, allows actomyosin 
interaction and contraction of muscle cell occur in response to Ca2+ 
[12] and ACE converts Angiotensin I to Angiotensin II, an important 
mediator in secondary myocardial hypertrophy, post-myocardial 
infarction remodeling and heart failure [13,14].
Screening of other known mutations associated with the HCM 
was not found in any family members except for the TNNT2 and ACE 
polymorphism. The inheritance of TNNT2 and ACE polymorphisms 
revealed that the index patient was distinct from all other family 
members with respect to genotypes 5bp TNNT2 (II) and 287bp ACE 
(ID), while the elder brother and the father with the MYH7 mutation 
(CT at codon 923) had similar genotypes i.e. 5bp TNNT2 (ID) and 
287bp ACE (II) (Figure 2).
The Index patient with rare MYH7 (CT at codon 923) mutation 
had severe symptoms and early onset of disease which could be explained 
due to co-occurrence of ACE (ID) and TNNT2 (II) genotypes. Since 
his father and elder brother having different ACE (II) and TNNT2 
(ID) genotypes harboring same rare MYH7 mutation could have been 
protective, with father having mild symptoms with late onset of disease 
and elder brother had no clinical manifestation till now. Also it was 
reported that ‘D’ allele of 5bpTNNT2 gene polymorphism had higher 
frequency in Indian populations [15], suggesting it may have some 
selective advantage. So presence of ‘D’ allele in father and his elder 
brother could have been beneficial in counteracting pathogenic MYH7 
mutation.
Conclusions
The present family study suggested that the combinational effect 
of two or more variants may modify the phenotypic expression of the 
pathogenic mutation. In HCM, several private mutations have been 
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Figure 2: The Family pedigree showing affected and unaffected family members with genetic profile, present age and age of onset for the affected family members.
Family Member & 
Relation with ego
Age, Sex and 
Age of onset of 
disease
NYHA 
Class
Echocardiographic findings ECG Symptoms BMI BP (Sys/Dia)
PW (LV) Thickness
(mm)
IVS thickness 
(mm)
Proband 17yrs, M, 14yrs III 17 23 ST depression, 
Abnormal QRS 
complex
Severe symptoms like 
fatigue, chest pain, with mild 
SAM & MR.
24.9 116/74
Father 51yrs, M, 48yrs II 19 31 ST depression Mild symptoms with mild 
SAM & MR
31.4 108/72
Brother 20yrs, M, NA - 10 10 Normal No symptoms 20.3 105/68
Brother 22 yrs, M, NA - 9 7 Normal No symptoms 27.2 120/78
Mother 43 yrs, F , NA - 10 9 Normal No symptoms 31.9 120/84
Father’s Sister 50yrs, F, NA - 8 8 Normal No symptoms 31.8 148/96
Father’s Sister 45yrs, F, NA - 10 8 Normal No symptoms 33.7 128/76
BMI: Body Mass Index; BP: Blood pressure; ECG:Electrocardiogram; MR:Mitral Regurtitation; SAM:Systolic Anterior Motion; PW: Posterior Wall; LV; left ventricular; 
mm;Milli meter; Sys:Systolic; Dia:Diastolic (Range for Normal BMI ≤ 25; Normal BP = 120/80).
Table 1: Clinical findings of the all family members.
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reported, but cataloguing the same with clinical data will be a useful 
exercise for clinical practice with the larger picture of personalized 
genomic medicine in horizon.
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